Amphastar Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMPH research report →
Range $23 – $23
Price Chart
About the company
Amphastar Pharmaceuticals, Inc. , established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations.
- CEO
- Yongfeng Zhang
- IPO
- 2014
- Employees
- 1,976
- HQ
- Rancho Cucamonga, CA, US
Get TickerSpark's AI analysis on AMPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.20B
- P/E
- 12.93
- Fwd P/E
- 8.83
- PEG
- -3.04
- P/S
- 1.66
- P/B
- 1.52
- EV/EBITDA
- 7.83
- Div Yield
- 0.00%
- Gross Margin
- 46.81%
- Op Margin
- 18.74%
- Net Margin
- 13.27%
- ROE
- 12.59%
- ROIC
- 6.92%
Latest fiscal year · YoY change
- Revenue
- $719.89M-1.7%
- Gross Profit
- $356.06M-4.8%
- Op Income
- $140.40M
- Net Income
- $98.09M-38.5%
- EPS
- $2.10-36.2%
- OCF Growth
- -26.8%
- FCF Growth
- -29.7%
- 52W High
- $31.00
- 52W Low
- $16.65
- 50D MA
- $26.42
- 200D MA
- $22.38
- Beta
- 0.94
- RSI (14)
- 54
- Avg Volume
- 473.46K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Amphastar posted record Q3 revenue and profit, but gross margin softened as BAQSIMI pricing pressure and IMS remediation costs continued.· November 5, 2026
- Q3 revenue hit a record $207.6 million, up 8% year over year and 13% sequentially.
- Gross margin fell to 48% from 51% a year ago, mainly due to lower pricing on BAQSIMI, glucagon and epinephrine plus higher IMS manufacturing costs.
- BAQSIMI and Primatene MIST both set quarterly sales records, while ipratropium bromide and teriparatide added meaningfully to growth.
- IMS remediation is still weighing on supply timing and costs, with management expecting a few more quarters of elevated expense.
- Fourth-quarter sales are expected to grow in the high single-digit range versus last year, despite a modest IMS drag.
Third-quarter revenue was $207.6 million, up 8% from $191.8 million in the prior-year period and 13% sequentially. Gross margin was 48% versus 51% a year ago, and cost of revenues rose 16% to $108 million from $93.2 million. Net income was $37.8 million, or $0.87 per share, versus $17.4 million, or $0.37 per share, last year; adjusted net income was $49.3 million, or $1.14 per share, versus $44.7 million, or $0.93 per share. Cash flow from operations was approximately $43.3 million. For the fourth quarter, management expects sales to increase in the high single-digit range year over year, including a modest slowdown in IMS sales as corrective actions continue.
Management emphasized a three-part growth strategy: maximize commercial products, advance complex generics and biosimilars, and progress proprietary development. Dan Dischner highlighted record BAQSIMI and Primatene MIST sales, contributions from recent launches, and continued investment in the pipeline and manufacturing base. The tone was constructive, with repeated emphasis on Amphastar’s U.S. manufacturing footprint, vertical integration, and long-term opportunity set.
Bill Peters detailed the financial drivers behind the quarter: BAQSIMI sales of $58.8 million, Primatene MIST sales of $31.5 million, lidocaine sales of $16.6 million, epinephrine sales of $15.3 million, glucagon sales of $8.6 million, and other pharmaceutical product sales of $70.2 million. He said gross margin compression came mainly from lower selling prices on BAQSIMI, glucagon and the epinephrine multi-dose vial, plus $2 million to $3 million of extra IMS expense this quarter. He also noted SG&A fell to $16.8 million from $39.5 million due to a prior-year legal settlement, R&D declined to $20.1 million from $22.3 million, and the board authorized an additional $50 million for share repurchases.
Analysts focused on BAQSIMI duplicate discounts, the IMS remediation timeline, and the outlook for 2027 launches. Management said it is not yet at the targeted 80% reduction in duplicate discounting, but progress has improved pricing versus the prior two quarters; they do not expect BAQSIMI pricing to return to prior levels because the issue will remain a headwind. On IMS, management said the FDA receives routine updates, the company has a broader corrective plan than what was specifically requested, and extra expense should run a bit higher than $2 million to $3 million in each of the next two or three quarters. For the insulin aspart biosimilar, they reiterated a 2027 launch target subject to FDA approval but said there is no firm launch date yet.
The company delivered record revenue, record BAQSIMI and Primatene MIST sales, and strong operating cash flow, showing the commercial base remains healthy. Management also pointed to improving BAQSIMI pricing trends, continued growth from ipratropium bromide and teriparatide, and a potential 2027 insulin biosimilar launch as future catalysts.
Gross margin remains under pressure from BAQSIMI pricing, glucagon, epinephrine and higher IMS remediation costs, and management said BAQSIMI pricing likely will not recover to prior levels. IMS is still creating operational drag and higher expense for the next few quarters, while some new programs face competitive or timing uncertainty, including a limited opportunity for AMP-018 and no firm date yet for insulin aspart.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 73.6%
- Shares Outstanding
- 42.65M
- Float Shares
- 31.41M
of shares held by institutions
215 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 5.12M | ▼ 106.20K |
| Vanguard Group Inc | 2.61M | ▼ 22.88K |
| Dimensional Fund Advisors LP | 2.38M | ▲ 77.88K |
| State Street Corp | 1.67M | ▲ 31.93K |
| American Century Companies Inc | 1.59M | ▲ 408.44K |
| Vanguard Capital Management LLC | 1.24M | ▼ 242.60K |
| Marshall Wace, Llp | 1.22M | ▲ 149.93K |
| D. E. Shaw & Co., Inc. | 1.15M | ▲ 258.08K |
| Geode Capital Management, LLC | 970.45K | ▲ 612 |
| Fuller & Thaler Asset Management, Inc. | 922.96K | ▼ 26.27K |
| Vanguard Portfolio Management LLC | 803.87K | ▼ 5.70K |
| Lsv Asset Management | 731.22K | ▲ 89.20K |
Held by 325 ETFs
Biggest fund positions in AMPH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | PETERS WILLIAM J | other | 11,000 |
| Nov 16, 26 | PETERS WILLIAM J | sell | 11,000 |
| Nov 16, 26 | PETERS WILLIAM J | other | 11,000 |
| Nov 4, 26 | PETERS WILLIAM J | other | 16,000 |
| Nov 5, 26 | PETERS WILLIAM J | other | 11,000 |
| Nov 4, 26 | PETERS WILLIAM J | sell | 16,000 |
| Nov 5, 26 | PETERS WILLIAM J | sell | 12,631 |
| Nov 5, 26 | PETERS WILLIAM J | other | 11,000 |
| Nov 4, 26 | PETERS WILLIAM J | other | 16,000 |
| Sep 21, 26 | PETERS WILLIAM J | sell | 4,139 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMPH coverage
Recent articles, reports, and earnings notes.
No research on AMPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMPH report →Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
prnewswire.com · Nov 11
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 5
Amphastar Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates
zacks.com · Nov 5
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
prnewswire.com · Nov 5
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
zacks.com · Oct 29
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
prnewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.